GlassScriptPhysician profile
Hesum Chegini
NPI 1902197791
$7,343.49
in general payments reported to CMS, 2019-2025
27 companies · $2,059 in 2025
The $2,059 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $442 · 2023: $2,550 · 2024: $2,293 · 2025: $2,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,888 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,887.93 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,592.88 | 2022-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $1,197.39 | 2022-2025 | Evenity, Prolia, Tavneos |
| Ucb, INC. | $757.94 | 2022-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $539.81 | 2023-2025 | |
| Lilly USA, LLC | $433.76 | 2022-2025 | Taltz, Zepbound |
| Janssen Biotech, INC. | $429.17 | 2022-2025 | Tremfya |
| Glaxosmithkline, LLC. | $313.78 | 2023-2025 | Benlysta, Nucala |
| Mallinckrodt Hospital Products INC. | $288.73 | 2023-2025 | Acthar |
| Pfizer INC. | $268.58 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $256.00 | 2022-2025 | Lupkynis |
| Horizon Therapeutics Plc | $185.87 | 2022-2023 | Krystexxa, Tepezza, Uplizna |
| Organon LLC | $155.65 | 2023-2025 | Renflexis, Hadlima |
| Sandoz INC. | $138.27 | 2023-2025 | Hyrimoz, Jubbonti |
| Radius Health, INC. | $129.03 | 2022-2024 | Tymlos |
| Alexion Pharmaceuticals, INC. | $98.49 | 2022-2024 | Strensiq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $89.97 | 2023-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $81.41 | 2024-2025 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals International, Plc | $73.58 | 2024 | Arcalyst |
| Genzyme Corporation | $70.85 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $59.14 | 2024-2025 | Saphnelo |
| Kiniksa Pharmaceuticals, LTD. | $58.85 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.89 | 2024 | Spevigo |
| Pacira Pharmaceuticals Incorporated | $20.68 | 2025 | Zilretta, Iovera |
| Biohaven Pharmaceutical Holding Company LTD. | $19.98 | 2022 | |
| Eisai INC. | $19.01 | 2023 | |
| Axsome Therapeutics, INC. | $18.10 | 2023 | Sunosi |
| Sun Pharmaceutical Industries INC. | $15.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hesum Chegini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.